An official website of the United States government 
Activity Outline
FDA Grand Rounds: FDA's work with African Swine Fever from a policy and regulatory perspective
June 10, 2021
Virtual
FDA Grand Rounds: FDA's work with African Swine Fever from a policy and regulatory perspective
June 10, 2021
Virtual
Activity Coordinators:
Sharron Watson (Sharron.Watson@fda.hhs.gov), Rokhsareh Shahidzadeh (Rokhsareh.Shahidzadeh@fda.hhs.gov)
Series Description
The FDA Grand Rounds is webcast every other month to highlight cutting-edge research underway across the agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities.
Lecture Description
African swine fever (ASF) is a highly contagious disease of swine (both farm-raised and wild) that causes significant economic losses to the swine industry in affected countries. The primary transmission of ASF is either pig-to-pig or through a pig consuming contaminated pork, but the virus can also be spread through ticks and inadvertently by humans. The ASF virus is considered a foreign animal disease (FAD) and USDA has the U.S. government lead for prevention, surveillance, and control. Data has emerged to show that animal food can also be a transmission vehicle, and FDA is the primary U.S. government responsible for the oversight of the animal food supply.
FDA and USDA have been working collaboratively on thinking through the complexities of animal food as a vector for ASF transmission. FDA is working to educate the pork and animal food industries on the importance of pre-market review for any substances utilized to mitigate the risk of ASF in animal food and has committed to expedited review of potential food additives used for this purpose. FDA has developed an ASF response plan to identify critical activities needed to detect and respond to the presence of the virus in animal food to prevent further spread of the disease and to facilitate swift normalization for the production of and distribution of animal food in the event of an outbreak. FDA is evaluating the feasibility of developing laboratory detection methods to enhance the biosecurity of imported animal food while maintaining the ability of U.S. grain producers to export their product.
African swine fever (ASF) is a highly contagious disease of swine (both farm-raised and wild) that causes significant economic losses to the swine industry in affected countries. The primary transmission of ASF is either pig-to-pig or through a pig consuming contaminated pork, but the virus can also be spread through ticks and inadvertently by humans. The ASF virus is considered a foreign animal disease (FAD) and USDA has the U.S. government lead for prevention, surveillance, and control. Data has emerged to show that animal food can also be a transmission vehicle, and FDA is the primary U.S. government responsible for the oversight of the animal food supply.
FDA and USDA have been working collaboratively on thinking through the complexities of animal food as a vector for ASF transmission. FDA is working to educate the pork and animal food industries on the importance of pre-market review for any substances utilized to mitigate the risk of ASF in animal food and has committed to expedited review of potential food additives used for this purpose. FDA has developed an ASF response plan to identify critical activities needed to detect and respond to the presence of the virus in animal food to prevent further spread of the disease and to facilitate swift normalization for the production of and distribution of animal food in the event of an outbreak. FDA is evaluating the feasibility of developing laboratory detection methods to enhance the biosecurity of imported animal food while maintaining the ability of U.S. grain producers to export their product.
References
- FDA’s African Swine Fever web page available at: https://www.fda.gov/animal-veterinary/safety-health/african-swine-fever
Series Objectives
- Discuss the research conducted at the FDA
- Explain how FDA science impacts public health
Learning Objectives After completion of this activity, the participant will be able to:
- Explain what African Swine Fever (ASF) is and how it is transmitted
- Explain the global implications associated with an ASF outbreak
- List some of the organizations and government agencies that may collaborate in the investigation of an ASF outbreak
- Explain the key strategies in FDA’s ASF Response Plan
- Describe some of the challenges faced by FDA in responding to an ASF outbreak
Target Audience
This activity is intended for physicians, pharmacists, nurses, and other scientists within the agency and external scientific communities.
This activity is intended for physicians, pharmacists, nurses, and other scientists within the agency and external scientific communities.
Agenda
Lecture 1 June 10, 2021
Lecture 1 June 10, 2021
| Time | Topic | Speaker |
|---|---|---|
| 12:00 - 1:00 PM EDT | FDA's work with African Swine Fever from a policy and regulatory perspective |
Linda Benjamin, PhD Jeanette Murphy, M.S. |
Continuing Education Accreditation
In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
CME
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE
This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-21-016-L04-P for 1.00 contact hour(s).
CNE
FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).
Requirements for Receiving CE Credit
Physicians, pharmacists, nurses, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.
Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.
Important Note regarding completion of evaluations and receiving credit
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
Disclosure
Faculty
Planning Committee
CE Consultation and Accreditation Team
Faculty
- Benjamin, Linda, PhD, Supervisor, Animal Food Safety Team, FDA, Center for Veterinary Medicine - nothing to disclose
- Murphy, Jeanette, M.S., Deputy Director for Foods, CVM Office of Surveillance and Compliance - nothing to disclose
Planning Committee
- Dinatale, Miriam, DO, Team Leader, Food and Drug Administration - nothing to disclose
- Pfundt, Tiffany, PharmD, Program Coordinator, FDA/CDER/OTBB - Disclosure not received.
- Wheelock, Leslie, RN, MS, Director, OSPD, FDA, OC, OCS, OSPD - nothing to disclose
CE Consultation and Accreditation Team
- Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose
Registration Information
Registration is complimentary; therefore refunds are not applicable.
Registration is complimentary; therefore refunds are not applicable.
U.S. Food and Drug Administration